Abstract
8531 Background: Early results of a randomized phase III GITMO/FIL study (www.clinicaltrials.gov NCT00435955) comparing CHOP-R vs. R-HDS + ASCT as primary treatment in134 FL pts, aged ≤60 yrs with aaIPI>1/IIL score>2, showed superior disease control with R-HDS but no OS advantage (Ladetto et al, Blood 2008). We here present an updated analysis from July 2013 at a median follow-up (MFU) of 9.5 yr including 125 pts of 134 originally randomized pts (61 CHOP-R/64 of R-HDS). Methods: Clinical features (CF) and treatment schedules have been already reported. Briefly, median age was 51 yrs. (22-60), M/F ratio 74/51, aaIPI 2-3 90%, retrospective FLIPI >2 60%, high LDH 49%, bulky disease 62%, B-symptoms 45%, BM+ 86%. CF were balanced among the two arms. Analysis was intention to treat and EFS the primary endpoint. Minimal residual disease was done by nested and RQ-PCR. Results: CR rate was 70.4% (57% with CHOP-R and 83% with R-HDS, p < .001); 64% patients achieved a Molecular Remission (MR). At MFU, 88 patients (7...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
